Cite
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab.
MLA
de Vries, Tessa, et al. “Pharmacology of Erenumab in Human Isolated Coronary and Meningeal Arteries: Additional Effect of Gepants on Top of a Maximum Effect of Erenumab.” British Journal of Pharmacology, vol. 181, no. 12, June 2024, pp. 1720–33. EBSCOhost, https://doi.org/10.1111/bph.16322.
APA
de Vries, T., Rubio, B. E., van den Bogaerdt, A., Dammers, R., Danser, A. H. J., Snellman, J., Bussiere, J., & MaassenVanDenBrink, A. (2024). Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab. British Journal of Pharmacology, 181(12), 1720–1733. https://doi.org/10.1111/bph.16322
Chicago
de Vries, Tessa, Beltrán, Eloísa Rubio, Antoon van den Bogaerdt, Ruben Dammers, A. H. Jan Danser, Josefin Snellman, Jeanine Bussiere, and Antoinette MaassenVanDenBrink. 2024. “Pharmacology of Erenumab in Human Isolated Coronary and Meningeal Arteries: Additional Effect of Gepants on Top of a Maximum Effect of Erenumab.” British Journal of Pharmacology 181 (12): 1720–33. doi:10.1111/bph.16322.